A compound of formula: J represents: Q is N or -CH-; X is O or O-CH 2 -; Y is -CH= or N; Z is O, NR 4, -CR 4a =N- or -N=CR 4a - whereby the latter two groups, together with the atoms to which they are attached, form a 6 membered ring; R 1 is C 1-6 alkyl, branched or unbranched, or C 3-6 cycloalkyl, each optionally substituted by a hydroxyl group; R 2a is H, halo, saturated or unsaturated branched or unbranched C 1-8 alkylene chain, wherein one or more carbons are optionally replaced by a heteroatom(s) independently selected from -O-, -N- and/or S m and the chain is optionally substituted by one or more halogen atoms R 2b is H, halo, C 1-6 alkoxy or C 1-6 alkyl optionally substituted by OH; R 2 and R 3 each independently represent H, C 1-4 alkyl, halogen; C 1-4 haloalkyl, O(C 1-4 alkyl), O(C 1-4 haloalkyl), CN, SO 2 R 5, C OR 6 with the proviso that R 2 and R 3 do not both represent H concomitantly, or R 2 and R 3 together with the carbons to which they are attached form a six membered aromatic ring or a heteroaromatic ring comprising a nitrogen atom; R 4 is H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6 aryl, a 5 or 6 membered heteroaryl or a 5 or 6 membered heterocyclic group, wherein said aryl, heteroaryl or heterocyclic group is substituted with 0 to 3 substituents selected from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, amino, C 1-4 mono or di-alkyl amino, C 1-4 mono or di-acyl amino, S q C 1-6 alkyl, C 0-6 alkylC C 1-6 alkyl or C 0-6 alkylC C 1-6 heteroalkyl; R 4a is H or C 1-3 alkyl; R 5 is H or C 1-4 alkyl; R 6 is H or C 1-4 alkyl; m is 0, 1 or 2; q is 0, 1 or 2; a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, for use as an anti-viral agent in the treatment or prophylaxis of viral infection. Q is N or -CH-; X is O or O-CH 2 -; Y is -CH= or N; Z is O, NR 4, -CR 4a =N- or -N=CR 4a - whereby the latter two groups, together with the atoms to which they are attached, form a 6 membered ring; R 1 is C 1-6 alkyl, branched or unbranched, or C 3-6 cycloalkyl, each optionally substituted by a hydroxyl group; R 2a is H, halo, saturated or unsaturated branched or unbranched C 1-8 alkylene chain, wherein one or more carbons are optionally replaced by a heteroatom(s) independently selected from -O-, -N- and/or S m and the chain is optionally substituted by one or more halogen atoms R 2b is H, halo, C 1-6 alkoxy or C 1-6 alkyl optionally substituted by OH; R 2 and R 3 each independently represent H, C 1-4 alkyl, halogen; C 1-4 haloalkyl, O(C 1-4 alkyl), O(C 1-4 haloalkyl), CN, SO 2 R 5, C OR 6 with the proviso that R 2 and R 3 do not both represent H concomitantly, or R 2 and R 3 together with the carbons to which they are attached form a six membered aromatic ring or a heteroaromatic ring comprising a nitrogen atom; R 4 is H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6 aryl, a 5 or 6 membered heteroaryl or a 5 or 6 membered heterocyclic group, wherein said aryl, heteroaryl or heterocyclic group is substituted with 0 to 3 substituents selected from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, amino, C 1-4 mono or di-alkyl amino, C 1-4 mono or di-acyl amino, S q C 1-6 alkyl, C 0-6 alkylC C 1-6 alkyl or C 0-6 alkylC C 1-6 heteroalkyl; R 4a is H or C 1-3 alkyl; R 5 is H or C 1-4 alkyl; R 6 is H or C 1-4 alkyl; m is 0, 1 or 2; q is 0, 1 or 2; a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, for use as an anti-viral agent in the treatment or prophylaxis of viral infection.